Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Advanced or Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619365
What this trial is testing

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
Washington University School of Medicine 60
Large-scale testing (Phase 3)Looking for participantsNCT06926868
What this trial is testing

Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Who this might be right for
Breast Neoplasms
Bristol-Myers Squibb 600
Testing effectiveness (Phase 2)Ended earlyNCT00351858
What this trial is testing

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsBreast Cancer
Neovii Biotech 40
Testing effectiveness (Phase 2)UnknownNCT05792410
What this trial is testing

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Who this might be right for
HER2 Low Advanced or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Early research (Phase 1)Ended earlyNCT02598427
What this trial is testing

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Kimberly Blackwell 1
Not applicableLooking for participantsNCT06210776
What this trial is testing

Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Who this might be right for
HER2-positive Breast CancerHER2-low Breast CancerBreast Cancer+1 more
Daiichi Sankyo 800
Testing effectiveness (Phase 2)Looking for participantsNCT06642545
What this trial is testing

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3